Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population
This study provides early economic insights, based on general population preferences, suggesting that epcoritamab's subcutaneous injection and outpatient administration beyond Cycle 2 may be associated with improved QOL compared to other therapies, regardless of efficacy and safety.
Authors
- Kanako Ishii (ORCID: https://orcid.org/0000-0002-0183-9508)
- Isao Kawaguchi (ORCID: https://orcid.org/0000-0002-0993-9466)
- Fujio Matsuyama
- Tatsunori Murata (ORCID: https://orcid.org/0000-0003-0132-5424)
- Shigeo Fuji (ORCID: https://orcid.org/0000-0002-8088-6088)
- Laura Liao
- Sarah Alhasani
- Kana Takaura
- Hiroshi Ando
Institutions
- Genmab (United States) (US)
- AbbVie (United States) (US)
- Center for Assessment (US)
- Osaka International Cancer Institute (JP)
- AbbVie (Japan)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1080/13696998.2026.2627829
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00